Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

Le résumé fourni par la source

In Figure 3C, the representative image for ASO10A was inadvertently duplicated as ASO1B. Data from the fourth experimental replicate was also omitted from Figure 3D. The original Figure 3 and accompanying legend appear below. Figure 3 PR-LncRNA1 and 10 silencing leads to increased proliferation and stemness. U87-MG cells were transfected with specific ASOs for the PR-LncRNAs indicated. ( A,B ) Transfected cells were examined for PR-LncRNA1 and PR-LncRNA10 expression by quantitative reverse transcription polymerase chain reaction (n = 4). ( C ) Representative immunofluorescence of P-H3 in U87MG cells under the conditions indicated. ( D ) Quantification of the number of P-H3 positive cells under the conditions indicated (n = 4). ( E ) Quantification of mRNA levels of p21 cip , Bax and SerpinB5 in cells transfected with ASOs for PR-LncRNA1 and 10 and compared to cells with a control ASO ( F ) Expression of PR-LncRNA 1,5 and 10 in indicated conventional cell lines (U87-MG, U251, U373 and A172) and glioma stem cells (GNS166, GNS179 and GB1) ( G ) Quantification of primary oncospheres formed in ASO-transfected cells after 10 days in culture (n = 3). ( H ) Quantification of number of secondary oncospheres generated from disaggregating primary oncospheres in ASO-transfected and control cells. Numbers were assessed after 10 days in culture (n = 3). Asterisks (*,**and ***) indicate statistical significance ( p < 0.05, p < 0.01, and p < 0.001, respectively). Full size image

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.